%D8%A8%D9%8A%D9%88%D8%A8%D8%B1%D9%8A%D9%86%D9%88%D8%B1%D9%81%D9%8A%D9%86%D8%A8%D9%88%D9%BE%D8%B1%D9%86%D9%88%D8%B1%D9%81%DB%8C%D9%86%D0%91%D1%83%D0%BF%D1%80%D0%B5%D0%BD%D0%BE%D1%80%D1%84%D0%B8%D0%BD%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A7%81%E0%A6%AA%E0%A7%8D%E0%A6%B0%E0%A6%BF%E0%A6%A8%E0%A6%B0%E0%A6%AB%E0%A6%BF%E0%A6%A8BuprenorphineBuprenorfinBwprenorffinBuprenorphinBuprenorphin%CE%92%CE%BF%CF%85%CF%80%CF%81%CE%B5%CE%BD%CE%BF%CF%81%CF%86%CE%AF%CE%BD%CE%B7BuprenorphineBuprenorfinaBuprenorfina%D8%A8%D9%88%D9%BE%D8%B1%D9%86%D9%88%D8%B1%D9%81%DB%8C%D9%86BuprenorfiiniBupr%C3%A9norphine%D7%91%D7%95%D7%A4%D7%A8%D7%A0%D7%95%D7%A8%D7%A4%D7%99%D7%9FBuprenorfinBuprenorfin%D4%B2%D5%B8%D6%82%D5%BA%D6%80%D5%A5%D5%B6%D5%B8%D6%80%D6%86%D5%AB%D5%B6Buprenorfina%E3%83%96%E3%83%97%E3%83%AC%E3%83%8E%E3%83%AB%E3%83%95%E3%82%A3%E3%83%B3%E1%83%A1%E1%83%A3%E1%83%91%E1%83%9D%E1%83%A2%E1%83%94%E1%83%A5%E1%83%A1%E1%83%98%EB%B6%80%ED%94%84%EB%A0%88%EB%85%B8%EB%A5%B4%ED%95%80BuprenorfineBuprenorfin%E0%AC%AC%E0%AD%81%E0%AC%AA%E0%AD%8D%E0%AC%B0%E0%AD%87%E0%AC%A8%E0%AC%B0%E0%AD%8D%E0%AC%AB%E0%AC%BF%E0%AC%A8BuprenorfinaBuprenorfinaBuprenorfin%C4%83%D0%91%D1%83%D0%BF%D1%80%D0%B5%D0%BD%D0%BE%D1%80%D1%84%D0%B8%D0%BDBuprenorfinBuprenorfinBuprenorfin%E0%B8%9A%E0%B8%B4%E0%B8%A7%E0%B8%9E%E0%B8%A3%E0%B8%B5%E0%B8%99%E0%B8%AD%E0%B8%A3%E0%B9%8C%E0%B8%9F%E0%B8%B5%E0%B8%99Buprenorphine%D0%91%D1%83%D0%BF%D1%80%D0%B5%D0%BD%D0%BE%D1%80%D1%84%D1%96%D0%BDBuprenorphineQ407721%E4%B8%81%E4%B8%99%E8%AB%BE%E5%95%A1
about
sameAs
P1889
Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentOptimal Treatment of Veterans With PTSD and Comorbid OUDXRB vs. SLB in Jail and at Re-entry: Pilot, Proof of ConceptHigh Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics OpioidSafety and Tolerability of Buprenorphine/Naloxone Film StripsInduction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/NaloxoneClinical Trial of Integrated Treatment for Pain and Opioid DependenceBuprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back PainPharmacokinetic Interactions Between Buprenorphine and Tipranavir/RitonavirSustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent IndividualsNorspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar SpineSafety and Efficacy of Probuphine in the Treatment of Opioid DependenceTreatment of Polydrug-Using Opiate Dependents During WithdrawalBuprenorphine Maintenance for Opioid-Addicted Persons in Jail and Post-ReleaseIntensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African AmericansStudy of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)Buprenorphine for Late-Life Treatment Resistant DepressionEffects of Voriconazole on the Pharmacokinetics and Pharmacodynamics of Oral Buprenorphine: A Two-phase Cross-over Study in Healthy SubjectsBlinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence SyndromeThe Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy VolunteersPrescription Opioid Abuse Among Pain Patients: Predictors of RelapseA Double-Blind Study of Buprenorphine Treatment of Acute SuicidalityA Study of Thienorphine Hydrochloride Tablets in Relapse Prevention Treatment of Opioid DependenceUse of Transcranial Magnetic Stimulation to Reduce Craving for Individuals With Opioid Use Disorder Taking BuprenorphineAdd-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive EpisodeClinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 HoursMedication Maintenance Therapy in Community Pharmacy SettingsAlternate Day Buprenorphine Administration, Phase IX - 14Buprenorphine-Fentanyl Interaction StudyBuprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal SymptomatologyMOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy StudyStudy of a Novel Subcutaneous Depot Formulation of BuprenorphineBuprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent IndividualsClinical Decision Support to Implement ED-initiated Buprenorphine for OUDEmergency Department Connection to Care With Buprenorphine for Opioid Use DisorderA Strategy to Improve Success of Treatment Discontinuation in Buprenorphine RespondersBuprenorphine Naltrexone-P1 A-CocaineThe Effects of Opioid Taper on Opioid-Induced HyperalgesiaBuprenorphine Disposition and Clinical Effects
P4844
A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid AddictionBuprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and childNew developments in managing opioid addiction: impact of a subdermal buprenorphine implant.Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studiesPractical considerations for the clinical use of buprenorphine.Pharmacologic treatments for opioid dependence: detoxification and maintenance options.A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence.Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.Advances in the delivery of buprenorphine for opioid dependence.Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine.A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.The prevalence of borderline personality among buprenorphine patients.Treatment of opioid dependence with buprenorphine: current update.Norspan® Patches Versus Tramadol in Subjects With Chronic, Moderate to Severe Osteoarthritis Pain in the Hip Knee and/or Lumbar SpineYoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone.Physicians'/Providers' alert: pain management for construction workersMedication-assisted treatment for opioid use disorder
P921
description
Läkemedel vid opiatberoende
@sv
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
name
Buprenorfiini
@fi
Buprenorfin
@cs
Buprenorfin
@da
Buprenorfin
@hr
Buprenorfin
@hu
Buprenorfin
@nb
Buprenorfin
@sh
Buprenorfin
@sr-el
Buprenorfin
@sv
Buprenorfina
@es
type
label
Buprenorfiini
@fi
Buprenorfin
@cs
Buprenorfin
@da
Buprenorfin
@hr
Buprenorfin
@hu
Buprenorfin
@nb
Buprenorfin
@sh
Buprenorfin
@sr-el
Buprenorfin
@sv
Buprenorfina
@es
altLabel
(-)-buprenorphine
@cy
(-)-buprenorphine
@en
(−)-buprenorphine
@en
17-cyclopropylmethyl-4,5alpha- ...... 6,14-endo-ethanomorphinan-3-ol
@cy
17-cyclopropylmethyl-4,5alpha- ...... 6,14-endo-ethanomorphinan-3-ol
@en
17-cyclopropylmethyl-4,5α-epox ...... 6,14-endo-ethanomorphinan-3-ol
@en
2-(N-cyclopropylmethyl-4,5alph ...... pha-yl)-3,3-dimethyl-2-butanol
@cy
2-(N-cyclopropylmethyl-4,5alph ...... pha-yl)-3,3-dimethyl-2-butanol
@en
2-(N-cyclopropylmethyl-4,5α-ep ...... -6α-yl)-3,3-dimethyl-2-butanol
@en
2-[3-cyclopropylmethyl-11-hydr ...... -16-yl]-3,3-dimethyl-2-butanol
@en
prefLabel
Buprenorfiini
@fi
Buprenorfin
@cs
Buprenorfin
@da
Buprenorfin
@hr
Buprenorfin
@hu
Buprenorfin
@nb
Buprenorfin
@sh
Buprenorfin
@sr-el
Buprenorfin
@sv
Buprenorfina
@es